Skip to main content

Recombinant Human EMMPRIN/CD147 (aa 138-323) His Protein, CF

Bio-Techne includes R&D Systems | Catalog # 10611-EM

Isoform 1, HEK293 Expressed
Catalog #
Availability
Size / Price
Qty
Loading...
10611-EM-050

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human EMMPRIN/CD147 protein
Glu138-Ala323, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu138

Predicted Molecular Mass

21 kDa

SDS-PAGE

25-41 kDa, under reducing conditions

Activity

Measured by the ability of the immobilized protein to induce active MMP-1 secretion by NHLF human normal lung fibroblasts.
The ED50 for this effect is 0.70-5.60 μg/mL.

Scientific Data Images for Recombinant Human EMMPRIN/CD147 (aa 138-323) His Protein, CF

Recombinant Human EMMPRIN/CD147 (aa 138-323) His-tag Protein Bioactivity.

Recombinant Human EMMPRIN/CD147 (aa 138‑323) His‑tag (Catalog # 10611-EM) induces active MMP-1 secretion by NHLF human normal lung fibroblasts. The ED50 for this effect is 0.70-5.60 µg/mL.

Recombinant Human EMMPRIN/CD147 His-tag (aa 138-323) His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human EMMPRIN/CD147 His-tag (aa 138-323) Protein (Catalog # 10611-EM) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 25-42 kDa and 20-37 kDa, respectively.

Formulation, Preparation and Storage

10611-EM
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: EMMPRIN/CD147

Extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN), also known as basigin and CD147, is a 44-66 kDa, variably N- and O-glycosylated, type I transmembrane protein that belongs to the immunoglobulin superfamily (1-4). Human EMMPRIN is 269 amino acids (aa) in length and contains a 24 aa signal sequence, a 183 aa extracellular domain (ECD), a 21 aa transmembrane (TM) segment and a 41 aa cytoplasmic tail. The ECD contains one C2-type and one V-type Ig-like domain. There is one 385 aa splice variant that contains an extra N-terminal IgCAM domain and is found only in the retina (5). There are additional multiple potential isoform variants for EMMMPRIN. Two that have been characterized are 205 and 176 aa in length. The 176 aa isoform utilizes an alternative start site at Met94, while the 205 aa isoform contains an 11 aa substitution for aa 1-75. Notably, the 176 aa isoform heterodimerizes with the standard EMMPRIN isoform and down-modulates its activity. This is in contrast to EMMPRIN homodimers that show full biological activity (6). EMMPRIN is expressed in areas of tissue remodeling, including endometrium, placenta, skin, and regions undergoing angiogenesis (1, 2, 7-10). It is also expressed on cells with high metabolic activity, such as lymphoblasts, macrophages and particularly tumor cells (2, 11). On such cells, EMMPRIN is often co-expressed with the amino acid transporter CD98h (12). EMMPRIN also interacts with caveolin-1 (via its C2-like domain), and this reduces the level of EMMPRIN glycosylation and subsequent EMMPRIN multimerization and activity (13). In addition, EMMMPRIN is reported to complex with both annexin II and beta1 integrins alpha3 and alpha6, an interaction that contributes to tumor growth and metastasis (14-16). Finally, the soluble calcium-binding protein S100A9 has now been identified as a ligand for EMMPRIN, and may mediate many of the tumorigenic activities attributed to EMMPRIN (17). EMMPRIN's TM sequence contains a charged aa (Glu), and a Pro important for intracellular interactions with cyclophilins (CyP) (3, 18, 19). CyPA (cyclosporin A receptor) and CyP60 interactions with the TM segment promote leukocyte inflammatory chemotaxis and surface expression of EMMPRIN, respectively (18, 19). An active 22 kDa fragment can be shed from tumor cells by MT1-MMP (1). Tumor cells can also release active, full-length EMMPRIN in microvesicles (20, 21). Functionally, EMMPRIN is known to induce urokinase-type plasminogen activator (uPA), VEGF, hyaluronan and multiple MMPs (1, 2, 8-10). Human EMMPRIN (269 aa) shows 58%, 58%, 62% and 52% aa identity with mouse, rat, cow and chick EMMPRIN, respectively. It also shows 25% and 38% aa identity with the related proteins, embigin and neuroplastin (SDR-1), respectively. SARS-CoV-2 invades host cells via two receptors: angiotensin-converting enzyme 2 (ACE2) and EMMPRIN. Spike protein (SP) from virus binds to ACE2 or EMMPRIN on the host cell, mediating viral invasion and dissemination of virus among other cells (22). EMMPRIN is a second entry receptor for SARS-CoV-2 (22). It is present in multiple cellular types in lung and highly expressed in type II pneumocytes and macrophages at the edges of the fibrotic zones (22). Therefore, the blockade of EMMPRIN could also play a beneficial role in pulmonary fibrosis due to COVID-19 (22).

References

  1. Gabison, E. E. et al. (2005) Biochimie 87:361.
  2. Yurchenko, V. et al. (2006) Immunology 117:301.
  3. Kasinrerk, W. et al. (1992) J. Immunol. 149:847.
  4. Iacono, K.T. et al. (2007) Exp. Mol. Pathol. 83:283.
  5. Hanna, S. M. et al. (2003) BMC Biochem. 4:17.
  6. Liao, C-G. et al. (2011) Mol. Cell. Biol. 31:2591.
  7. Riethdorf, S. et al. (2006) Int. J. Cancer 119:1800.
  8. Braundmeier, A. G. et al. (2006) J. Clin. Endocrinol. Metab. 91:2358.
  9. Tang, Y. et al. (2006) Mol. Cancer Res. 4:371.
  10. Quemener, C. et al. (2007) Cancer Res. 67:9.
  11. Wilson, M. C. et al. (2005) J. Biol. Chem. 280:27213.
  12. Xu, D. and M. E. Hemler, (2005) Mol. Cell. Proteomics 4:1061.
  13. Tang, W. et al. (2004) Mol. Biol. Cell 15:4043.
  14. Zhao, P. et al. (2010) Cancer Sci. 101:387.
  15. Dai, J. et al. (2009) BMC Cancer 9:337.
  16. Li, Y. et al. (2012) J. Biol. Chem. 287:4759.
  17. Hibino, T. et al. (2013) Cancer Res. 73:172.
  18. Arora, K. et al. (2005) J. Immunol. 175:517.
  19. Pushkarsky, T. et al. (2005) J. Biol. Chem. 280:27866.
  20. Egawa, N. et al. (2006) J. Biol. Chem. 281:37576.
  21. Sidhu, S. S. et al. (2004) Oncogene 23:956.
  22. Ulrich, H. et al. (2020) Stem Cell Rev. and Rep., https://doi.org/10.1007/s12015-020-09976-7.

Long Name

Extracellular Matrix Metalloproteinase Inducer

Alternate Names

Basigin, BSG, CD147

Entrez Gene IDs

682 (Human); 12215 (Mouse); 102121721 (Cynomolgus Monkey)

Gene Symbol

BSG

UniProt

Additional EMMPRIN/CD147 Products

Product Documents for Recombinant Human EMMPRIN/CD147 (aa 138-323) His Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human EMMPRIN/CD147 (aa 138-323) His Protein, CF

For research use only

Loading...
Loading...